Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/01/22
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 04/01/22
End: 05/31/26
Due: 05/31/27
Phase: N/A
Priority: Normal
Start: 09/22/21
End: 10/01/22
Due: 10/01/23
Phase: N/A
Priority: Normal
Start: 04/20/17
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 01/01/22
End: 12/30/24
Due: 12/30/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Belimumab for Treatment of cGVHD Following Allo-HCT | NCT05604742 | xuna | user2@example.com | None | 2022-01-01 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML | NCT05341050 | xuna | user2@example.com | None | 2022-04-01 | 2026-05-31 | 2027-05-31 | - | - | 2025-07-14 |
| A Study for PRO of CML in Real Word | NCT05092048 | xuna | user2@example.com | None | 2021-09-22 | 2022-10-01 | 2023-10-01 | - | - | 2025-07-14 |
| Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation | NCT04526223 | xuna | user2@example.com | None | 2017-04-20 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |
| Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT | NCT05604755 | xuna | user2@example.com | None | 2022-01-01 | 2024-12-30 | 2025-12-30 | - | - | 2025-07-14 |